A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, Quality Control of: 1,4,7,10,13-Pentaazacyclopentadecane, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 295-64-7, Name is 1,4,7,10,13-Pentaazacyclopentadecane, molecular formula is C10H25N5. In a Patent, authors is ，once mentioned of 295-64-7
The present invention aims to provide a compound having an MAGL inhibitory action, and useful as a prophylactic or therapeutic agent for neurodegenerative diseases (e.g., Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis and the like), anxiety disorder, pain (e.g., inflammatory pain, carcinomatous pain, nervous pain and the like), epilepsy and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
I hope this article can help some friends in scientific research. I am very proud of our efforts over the past few months and hope to 295-64-7, help many people in the next few years.Quality Control of: 1,4,7,10,13-Pentaazacyclopentadecane
Reference：
Metal catalyst and ligand design,
Ligand Template Strategies for Catalyst Encapsulation – NCBI